Viruses have been proposed as etiologic cofactors in the pathogenesis of HIVrelated neurological disease. To investigate the etiologic potential of Borna disease virus (BDV) in these disorders, two populations were studied: (1) 27 prospectively identi®ed patients with various neurological disorders were evaluated with BDV RT ± PCR (CSF, PBMC), and BDV serology, and (2) a separate group of 25 retrospectively studied patients with AIDS dementia complex was evaluated using BDV serology only. A novel, BDV p40 gene RT ± PCR assay was developed: conserved primers were used in a non-nested ampli®cation, detecting less than 100 BDV RNA copies and all of nine wildtype, con®rmed animal BDV infections. BDV seroprevalences were 12.5% and 8.0%, respectively, which are similar to the general HIV-infected population. None of the prospectively studied patients had detectable BDV RNA in their CSF or PBMC. Our ®ndings do not support the hypothesis that BDV infections are responsible for HIV-related neurological disorders.
Introduction
Two lines of evidence suggested that BDV may cause disease in HIV-infected patients. First, reports that BDV seroprevalence is higher among HIVinfected persons than among the general population (Auwanit et al, 1996; Bode et al, 1988) suggest that there may also be a higher prevalence of BDV infection in HIV-infected groups. Second, idiopathic neurologic disorders are frequently found among HIV-infected patients with advanced HIV disease. Other viruses have been proposed as possible cofactors in the etiology of HIV-related neurological disease and, in particular, AIDS dementia complex (ADC) (Lipton and Gendelman, 1995) .
The presence of viral antigens, BDV RNA and histopathological changes have been demonstrated in human brain tissues Haga et al, 1997; Salvatore et al, 1997) . Although some reports describe the presence of BDV RNA in PBMCs from psychiatric patients (Bode et al, 1995; Kishi et al, 1995b) , others have not detected BDV RNA in similar groups (Lieb et al, 1997; Richt et al, 1997; Sierra Honigmann et al, 1995) . In order to characterise the possible role of BDV as a viral cofactor in HIV-associated neurological disorders, we analysed cerebrospinal¯uid (CSF) and peripheral blood mononuclear cells (PBMC) with a newly developed RT ± PCR, and plasma or sera were evaluated with a previously published BDV serologic test (Caplazi et al, 1994) . This is the ®rst report to our knowledge that uses RT ± PCR to evaluate BDV infections among HIV-infected persons.
Results

Development of new BDV PCR primers
Novel BDV primers and probes were developed for this study. To identify conserved primer-binding sites, all BDV sequences published in the GenBank and EMBL sequence databases as of November 15, 1996, were identi®ed. The BDV p40 gene was the most often reported BDV sequence, with six independent sequence strings (BDVPT1P40, BDVPT2P40, BDVPT3P40 (Bode et al, 1995) , TOGBDVSEQ (Cubitt et al, 1994) , BD04608 (Briese et al, 1994) and S62821 . An alignment of all six available p40-sequences revealed an interrupted consensus sequence in which all six sequence strings had homology (Figure 1 ).
The consensus sequence was evaluated for suitable primers and probes that had the best sequence conservation, minimum intra-and interstrand duplex formation, minimum false priming sites, and the lowest melting temperature difference between the primers. The resulting BDV PCR primer pair (upper: BD139U, Lower: BD139L) and probe (BD139P) produce a product of 139 base pairs (Figure 1 ). BD139U and BD139P had no mismatches compared to the consensus sequence. The lower primer, BD139L, contained two mismatches relative to the consensus sequence at positions four and seven from the 5' end (Figure 1 ). To avoid potential ampli®cation problems due to these mismatches, BD139L was synthesised with inosine substitutions at positions four and seven because inosine can reportedly hybridise to any of the four normal nucleotides with approximately equal af®nity (Cassol et al, 1991) .
The PCR reaction was optimised with respect to MgCl 2 concentration (1, 1.5, 2 and 3 mM), glycerol concentration (0, 10 and 20%), TaqStart Antibody (0 or 0.5 ml per reaction), annealing temperature (50, 52, 54, 56, 58, 60 and 628C) , annealing time (20 s, 20 s plus 1 s cycle, 45 s) and denaturation temperature (95, 94 and 938C) . In the RT step, reactions primed with the speci®c BDV primer (BD139U) produced more PCR product than reactions primed with random hexamers.
The sensitivity of the BD139 RT ± PCR assay was tested in three ways. Conservation of the primer sequences was evaluated by testing brain tissues from nine animals with documented BDV infections (classical clinical syndrome and positive brain tissues by immunohistochemistry), including six horses, two sheep and one donkey. All nine cases were positive in the BD139 RT ± PCR assay. The lower limit of detection was evaluated ®rst by amplifying dilutions of RNA extracted from BDVpositive, cultured cells. This demonstrated BDV RT ± PCR positivity in RNA from 0.1 infected cell equivalents per reaction. The lower limit was further evaluated by amplifying dilutions of in vitro generated, quantitated p40 gene RNA, demonstrating detection of fewer than 100 BDV RNA copies per ampli®cation reaction.
Prospectively studied cohort with various neurological disorders Clinical and demographic data from the prospectively studied cohort are summarised in Table 1 . The median age of the 27 subjects (seven women) was 34 years (range, 28 ± 71). The median CD4 count at the time of spinal tap was 60 CD4 cells/ml (range 0 to 440). The median duration of followup was 175 days (range, 4 ± 433 days).
BDV RNA was not detected in any of the 27 PBMC or CSF specimens from HIV-infected patients with neurological diseases. The average amount of total RNA recovered from 26 of 27 PBMC specimens was 2.44 mg per specimen; the RNA content of one specimen could not be assessed for technical reasons. Since many patients in this cohort had lymphopenia secondary to advanced HIV disease, RNA yields varied from 0.12 ± 6.66 mg per PBMC specimen. Suitability of the extracted RNA for ampli®cation was con®rmed by semiquantitative beta-actin RT ± PCR, which was positive in all 26 RNA specimens tested. Since detectable RNA was not expected from 0.14 ml CSF, RNA levels in these specimens were not measured.
RNAs extracted from all 27 PBMC and CSF specimens were tested by BDV RT ± PCR in duplicate, and several positive and negative controls were included in every run, assuring consistent performance of the assay. In addition to the PCR data, BDV serologies performed on simultaneously collected sera from 16 of the 27 subjects revealed 2 (12.5%) that were positive (titers, 1 : 40 and 1 : 80). Retrospectively studied cohort with ADC Sera from 25 retrospectively studied HIV-infected subjects with a diagnosis of AIDS dementia complex (ADC) were evaluated by BDV serology: 2 of 25 (8.0%) subjects were antibody positive (both titers, 1 : 40).
Discussion
This study suggests that BDV infections do not play an important role in the pathogenesis of neurological illnesses among the two cohorts of HIV-infected subjects reported here. The prospectively studied cohort of 27 HIV-infected subjects with various neurological problems had no detectable BDV RNA in their CSF or PBMCs. The BDV seroprevalence in this group was 12.5% (2/16). The retrospectively studied cohort of 25 HIVinfected patients with AIDS dementia complex (ADC) was evaluated with BDV serologies only, resulting in a seroprevalence of 8.0% (2/25). These seroprevalences are similar to those previously reported for the general HIV-infected population (Auwanit et al, 1996; Bode et al, 1988) , suggesting no increased seroprevalence among those with neurological disorders.
The use of PBMC specimens for BDV detection was based on other reports that assessed BDV infections in humans (Bode et al, 1995; Kishi et al, 1995b; Lieb et al, 1997; Nakaya et al, 1996; Richt et al, 1997) . The topic of BDV RNA in PBMC specimens has stirred controversy. Sauder et al (1996) reported BDV RNA positivity by p24 and/or p40 RT ± PCR in 50% of PBMC specimens from 26 patients with psychiatric disorders. The PCR results were also con®rmed in a separate laboratory. Interestingly, most of the BDV RNApositive patients were BDV seronegative. In contrast, Lieb et al (1997) found no BDV RNA in blood from a different group of psychiatric patients attending the same hospital as used by Sauder et al (1996) . The negative PCR results from Lieb et al (1997) were also con®rmed in two separate laboratories. In view of this ongoing debate, we do not rule out the presence of BDV RNA in brain tissue on the basis of negative PBMC BDV RNA data.
The newly developed BDV RT ± PCR assay reported here has theoretical advantages over some existing BDV RT ± PCR methods. The single round of ampli®cation used here can provide better quantitation than the nested PCR protocols previously reported (Bode et al, 1995; Kishi et al, Sorg and Metzler, 1995; Zimmermann et al, 1994) , while reducing the risk of contamination inherent in nested methods. Although single round PCR can be less sensitive than nested PCR, sensitivity of less than 100 BDV RNA copies was achieved by detecting the PCR products with radioactive probes. Furthermore, the primers were based on conserved BDV sequences, improving the chances of detecting wild-type variants that may differ from characterised strains. Success in this respect was demonstrated by detecting BDV RNA in all of nine BDVinfected animal brain tissues.
Patients meeting our case de®nition do not typically undergo brain biopsies, so brain tissues from these subjects were not available. Instead, we studied CSF specimens to assess CNS infection. However, the RT ± PCR-negative results from CSF specimens in this study must be interpreted with caution. First, we are not aware of evidence that CSF contains BDV RNA in documented infections. Since BDV is cell associated, the failure to detect BDV-RNA in CSF could re¯ect the inadequacy of this specimen type. Second, we used small volumes of CSF for PCR and did not document RNA recovery from these specimens. The use of BDV RT ± PCR in CSF specimens was previously assessed in a cohort of schizophrenic patients in which no viral RNA was detected (Sierra Honigmann et al, 1995) . Attempts to culture BDV from CSF of three BDVseropositive patients suggested the presence of BDV, but the results were inconclusive because the cultures failed to propagate virus after passage .
BDV seroprevalence is reportedly higher in HIVinfected populations than in the general population, raising the possibility that HIV-infected patients are more frequently infected with BDV. Bode et al previously reported that HIV-infected individuals in the US and England have a higher BDV seroprevalence (7.8%) than the general population (2.0%) (Bode et al, 1988) . A study performed on HIV-1-infected subjects in Thailand reported BDV seroprevalences of 8.3% among prostitutes, 0% among IV drug users, and 2% among HIV-negative blood donors (Auwanit et al, 1996) . Surprisingly, a subgroup of HIV-infected patients with sexually transmitted diseases had a very high BDV seroprevalence (38%). Our study of HIV-infected individuals with neurological disorders revealed an overall BDV seropositivity of 9.8%, which is similar to the seroprevalence in unselected HIV-infected individuals from England and the US. The BDV PCR data reported here are the ®rst, to our knowledge, addressing actual viral replication among HIVinfected patients.
In summary, our RT ± PCR and serological data did not con®rm the presence of BDV in these cohorts of HIV-infected patients with neurological disorders. Although these negative results do not rule out BDV infections, they suggest that BDV infections are not a prominent etiology of neurological disorders in this immunocompromised population.
Materials and methods
Subjects
Two groups of subjects were studied. In the ®rst group, 27 HIV-infected patients with various neurological disorders were prospectively enrolled between May, 1995 and April, 1996 at the Zurich University Hospital. The enrollment criteria were (1) documented HIV infection and (2) spinal tap for any reason. At the time of spinal tap, at least 1 ml CSF and 16 ml anticoagulated blood (CPT Vacutainer, Becton Dickinson, Meylan, France) were collected. Within 4 h of collection, aliquots of peripheral blood mononuclear cells (PBMC), plasma and CSF were stored at 7708C. Clinical data from each patient were recorded on case report forms, including neuropsychological, cognitive, social, and motor disorders, history of animal contact, primary diagnosis, reason for spinal tap, results of brain imaging and followup information including de®nitive diagnosis (Table 1) . This research on human subjects was approved by the Ethical Committee (Human Subjects Review Board) of the University Hospital.
The second group of 25 patients was retrospectively identi®ed by searching the Swiss HIV Cohort Database (Ledergerber et al, 1994) for patients with (1) AIDS dementia complex (ADC) and (2) stored serum obtained within 1 month of ADC diagnosis. The 25 cases of ADC were diagnosed between November, 1988 and July, 1994 . The tested sera were closely matched to the date of ADC diagnosis, with a median difference between diagnosis and serum collection of 1 day.
BDV RT ± PCR
Searches of the GenBank and EMBL sequence databases (November 15, 1995) and sequence alignments were performed with GCG-8 software (Wisconsin Package, Version 8 for Silicon Graphics computers, Genetics Computer Group, Madison, WI, USA). Identi®cation of primers and probes in the BDV p40 consensus sequence was performed with Oligo software (OLIGO primer analysis software, Version 5.0 for Windows, National Biosciences, Inc., Annapolis Lane, Plymouth, MN, USA).
BDV RT ± PCR was performed as follows. RNA (®nal volume, 50 ml) was extracted from 5610 6 patient PBMCs, animal brain tissue, or control cell lines (BDV He/80-infected and -uninfected C6 cells) using the RNeasy Kit (Qiagen AG, Basel, Switzerland) or from 140 ml CSF using the QIAamp HCV Kit (Qiagen) according to the manufacturer's instructions. For PBMC extractions, RNA yields were determined by measuring¯uorescence with RiboGreen RNA quantitation reagent (Molecular Probes Europe BV, Leiden, The Netherlands) according to the manufacturer's instructions. Before reverse transcription, a mixture containing 5 ml RNA (10% of total extracted RNA) and 6 ml primer BD139U (5'-ATG TTT GCT AAT CCC AGG ACT-3') (1.3610 12 molecules, or 22 pmoles, primer) was denatured at 708C for 10 min. The mixture was then reverse transcribed using the Expand Reverse Transcriptase kit (Boehringer Mannheim AG, Rotkreuz, Switzerland) according to the manufacturer's instructions, except that the incubation proceeded for 10 min at 308C followed by 428C for an additional 45 min. Ampli®cation reactions (100 ml) containing 5 ml (25%) of the RT reaction and 50 ml 26 master mix [2.5 U AmpliTaq polymerase, 26 PCR buffer (both Perkin Elmer AG, Rotkreuz, Switzerland), 400 mM each dNTP, and 0.55 mg TaqStart antibody (Clonetech Laboratories Inc., Palo Alto, CA, USA), 5610 13 molecules (83 pmoles) of each primer, BD139U and BD139L (5'-CTG IGT IGT CTT TTC CCC GTA A-3')] were denatured (2 min at 948C), ampli®ed with 35 cycles (30 s at 948C, 45 s at 608C and 30 s at 728C) and extended for 5 min at 728C. Ampli®ed products were detected using ethidium bromide-stained gels and by liquid hybridisation. For hybridisation, 7 ml of PCR-product and 18 ml hybridisation solution [per hybridisation, 12.5 ml (50%) deionised formamide (Fluka, Buchs, Switzerland), 10 6 c.p.m. 32 Plabelled probe (BD139P: 5'-TGC GTT TGT TCA CGG AGG GGT GCC T-3'), 1 ml 5 M NaCl, 0.5 ml 5 mM each dNTP (dNTP Set, Pharmacia, Piscataway, NJ, USA) and water to 18 ml] were denatured at 978C for 5 min and hybridised by linear cooling to 308C over 15 min in a thermal cycler. Ten ml of hybridised mixture were electrophoresed in agarose gels (2.25% NuSieve/0.75% MP agarose (FMC, Rockland, ME, USA, and Boehringer-Mannheim, respectively). The gels were dried and autoradiographed. Radioactive hybridisation improved the sensitivity of detection by at least two orders of magnitude.
Beta-actin RT ± PCR Recovery of ampli®able PBMC RNA was documented by semi-quantitative beta-actin RT ± PCR. Primers designed in house correspond to beta-actin mRNA exons 3 (35up; 5'-GTCACCAACTGGGAC-GACATGGAGAA) and 4 (36low; 5'-CATGGCTG-GGGTGTTGAAGGTCTCA), resulting in a 171 bp PCR product. Ampli®cations were performed with the EZ rTth RNA PCR kit (Perkin-Elmer, Foster City, CA, USA) according to the suppliers suggestions. Brie¯y, 25 ml master mix (0.2 mM dNTP, 16 EZ buffer, 1.5 mM Mn(OAc) 2, 0.5 mM each primer and 0.15 U/ml rTth DNA polymerase) and 1 ml template RNA were ampli®ed in a T3 thermocycler (Biometra, Go È ttingen, Germany) as follows: 948C for 45 s, 628C for 20 min, 3 cycles of 958C for 15 s, 628C for 10 s and 728C for 30 s, then 22 cycles of 908C for 15 s, 628C for 10 s and 728C for 30 s, followed by 728C for 15 min and cooling to 48C. PCR products were electrophoresed in agarose gels and visualised with SYBR Gold nucleic acid stain (Molecular probes, Eugene, Oregon, USA). Digital images of the gels were created by scanning Polaroid photographs, and band intensities were determined using image analysis software (Intelligent Quanti®er, Biolmage, Ann Arbor, MI, USA). Copy numbers were calculated from band intensities by comparison to actin RT ± PCR products from PBMC RNA standards.
BDV serology and immunohistochemistry BDV serologies were performed as previously described (Caplazi et al, 1994) . Brie¯y, BDV strain He/80-infected MDCK or C6 cells were ®xed in acetone, incubated with threefold serum dilutions (378C, 1 h, washed three times, incubated with antihuman FITC conjugate (378C, 1 h), washed three times, counterstained with Evans blue, washed and mounted. Serum dilutions were scored as positive or negative based on the intensity of intranuclear signal under¯uorescent microscopy.
BDV infection in the brain tissue samples used as positive control material for PCR was established by immunohistochemistry as described (Caplazi et al, 1994) .
Paraf®n sections of brain tissues from nine animals suffering from clinically manifest Borna encephalitis were deparaf®nised and treated with 0.1% (w/v) protease (type XXVII, Sigma, Buchs, Switzerland). The monoclonal anti-BDV antibody 38/17 C1, recognising BDV p38, was used in a peroxidase streptavidin-biotin method (LSAB, DAKO, Glostrup, Denmark) with AEC as a chromogen. Speci®c signals were detected microscopically. A positive tissue sample and mock reactions without primary antibody were included in each assay to monitor the performance of the protocol.
